Nutriband Inc. (NASDAQ: NTRB), a leader in the development of transdermal pharmaceutical products, has announced its participation in the Emerging Growth Conference scheduled for August 20, 2025. The company's Chairman, Serguei Melnik, will deliver a live, interactive presentation, offering insights into Nutriband's pioneering AVERSA™ technology. This presentation may also include a Q&A session, allowing shareholders and the investment community to engage directly with the company's leadership.
The AVERSA™ technology represents a significant advancement in the fight against drug abuse, misuse, and accidental exposure. Designed to be incorporated into any transdermal patch, AVERSA™ aims to prevent the abuse of drugs with high potential for misuse, such as fentanyl. Nutriband's lead product under development is an abuse-deterrent fentanyl patch utilizing this technology, showcasing the company's commitment to addressing critical public health challenges.
Investors and industry observers can view the full details of Nutriband's announcement by visiting https://ibn.fm/dhj3J. For ongoing updates and news related to Nutriband Inc., the company's newsroom at https://ibn.fm/NTRB serves as a valuable resource.
The Emerging Growth Conference provides a platform for Nutriband to highlight its technological innovations and strategic direction to a broad audience of investors and industry professionals. This participation underscores the company's potential for growth and its role in advancing safer pharmaceutical solutions. The presentation could significantly influence investor perceptions and highlight the importance of abuse-deterrent technologies in the pharmaceutical industry.
